CTI BIOPHARMA CORP - FORM 10-K - EX-12.1 - STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - February 26, 2010

Attached files

file	filename
10-K - FORM 10-K - CTI BIOPHARMA CORP	d10k.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORP	dex311.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - CTI BIOPHARMA CORP	dex211.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - CTI BIOPHARMA CORP	dex231.htm
EX-10.23 - FORM OF EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT FOR EMPLOYEES - CTI BIOPHARMA CORP	dex1023.htm
EX-10.22 - FORM OF EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT FOR DIRECTORS - CTI BIOPHARMA CORP	dex1022.htm
EX-10.20 - REVISED DIRECTOR COMPENSATION POLICY - CTI BIOPHARMA CORP	dex1020.htm
EX-32 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - CTI BIOPHARMA CORP	dex32.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORP	dex312.htm

Exhibit 12.1

STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(in thousands)


								Year Ended December 31,
		2009			2008			2007			2006			2005
Net loss attributable to common shareholders		(116,763	)		(202,907	)		(148,305	)		(135,819	)		(102,505	)
Add: fixed charges		17,448			146,027			15,421			45,147			18,942

Earnings as defined		(99,315	)		(56,880	)		(132,884	)		(90,672	)		(83,563	)


Fixed charges:
Interest expensed and capitalized		16,939			145,332			14,827			44,582			17,559
Estimated interest component of rent		509			695			594			565			1,383

Total fixed charges		17,448			146,027			15,421			45,147			18,942

Ratio of earnings to fixed charges		(1	)		(1	)		(1	)		(1	)		(1	)

(1)	Earnings (as defined) for the period were insufficient to cover fixed charges by an amount equal to the net loss attributable to common shareholders for the period.